|
🐜
|
Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis
11 auth.
S. Gil-Perotín,
J. Castillo-Villalba,
L. Cubas-Nuñez,
R. Gasqué,
D. Hervás,
Josep Gomez-Mateu,
...
C. Alcalá,
F. Pérez-Miralles,
F. Gascón,
J. A. Domínguez,
B. Casanova
|
5 |
2019 |
5
🐜
|
|
🐜
|
Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study
8 auth.
C. Alcalá,
F. Gascón,
F. Pérez-Miralles,
S. Gil-Perotín,
A. Navarre,
I. Boscá,
...
F. Coret,
B. Casanova
|
5 |
2018 |
5
🐜
|
|
🐜
|
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis
17 auth.
B. Casanova,
I. Jarque,
F. Gascón,
J. Hernández-Boluda,
F. Pérez-Miralles,
J. de la Rubia,
C. Alcalá,
J. Sanz,
J. Mallada,
A. Cervelló,
...
A. Navarre,
María Carcelén-Gadea,
I. Boscá,
S. Gil-Perotín,
C. Solano,
M. Sanz,
F. Coret
|
5 |
2017 |
5
🐜
|
|
🐢
|
Optimal management of severe nausea and vomiting in migraine: improving patient outcomes
M. Láinez,
Ana García-Casado,
F. Gascón
|
5 |
2013 |
5
🐢
|
|
🐢
|
Escalation vs. Early Intense Therapy in Multiple Sclerosis
B. Casanova,
C. Quintanilla-Bordás,
F. Gascón
|
4 |
2022 |
4
🐢
|
|
🐜
|
Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies
10 auth.
F. Coret,
F. Pérez-Miralles,
F. Gascón,
C. Alcalá,
A. Navarre,
Ana Bernad,
...
I. Boscá,
M. Escutia,
S. Gil-Perotín,
B. Casanova
|
4 |
2018 |
4
🐜
|
|
🐬
|
Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing–remitting multiple sclerosis is effective and safe
C. Alcalá,
F. Gascón,
F. Pérez-Miralles,
J. A. Domínguez,
S. Gil-Perotín,
B. Casanova
|
4 |
2019 |
4
🐬
|
|
🐢
|
Sphenopalatine ganglion stimulation for the treatment of cluster headache
M. Láinez,
M. Puche,
Ana García,
F. Gascón
|
4 |
2014 |
4
🐢
|
